← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
RA Capital Nexus Fund III, L.P.
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001883840
Purchase history
- Companies traded
- 8
- Purchases · 12M
- 17
- Purchases · 24M
- 21
- Average purchase
- $35.2M
- Median purchase
- $4.8M
- Gross purchase value
- $739.6M
Companies: Artiva Biotherapeutics, Inc. | Bicara Therapeutics Inc. | Climb Bio, Inc. | Mineralys Therapeutics, Inc. | Parabilis Medicines, Inc. | Septerna, Inc. | Sionna Therapeutics, Inc. | SpyGlass Pharma, Inc.
21 SEC accession(s) · 21 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-31 | Artiva Biotherapeutics, Inc. | ARTV | Director | $455.7K | Open filing |
| 2026-07-28 | Artiva Biotherapeutics, Inc. | ARTV | Director | $412.8K | Open filing |
| 2026-07-23 | Artiva Biotherapeutics, Inc. | ARTV | Director | $58.3K | Open filing |
| 2026-07-23 | Artiva Biotherapeutics, Inc. | ARTV | Director | $2.6M | Open filing |
| 2026-07-22 | Parabilis Medicines, Inc. | PBLS | Director | $6.9M | Open filing |
| 2026-07-20 | Artiva Biotherapeutics, Inc. | ARTV | Director | $1.4M | Open filing |
| 2026-07-14 | Artiva Biotherapeutics, Inc. | ARTV | Director | $194.0K | Open filing |
| 2026-06-29 | Artiva Biotherapeutics, Inc. | ARTV | Director | $292.1K | Open filing |
| 2026-06-16 | Artiva Biotherapeutics, Inc. | ARTV | Director | $4.6M | Open filing |
| 2026-06-15 | Parabilis Medicines, Inc. | PBLS | Director | $423.8M | Open filing |
| 2026-06-11 | Artiva Biotherapeutics, Inc. | ARTV | Director | $7.7M | Open filing |
| 2026-05-13 | Artiva Biotherapeutics, Inc. | ARTV | Director | $75.0M | Open filing |
| 2026-03-31 | Mineralys Therapeutics, Inc. | MLYS | Director | $8.8M | Open filing |
| 2026-03-02 | Bicara Therapeutics Inc. | BCAX | Director | $4.8M | Open filing |
| 2026-02-11 | SpyGlass Pharma, Inc. | SGP | Director | $59.0M | Open filing |
| 2026-01-07 | Climb Bio, Inc. | CLYM | Director | 10% Owner | $24.9K | Open filing |
| 2025-12-15 | Climb Bio, Inc. | CLYM | Director | 10% Owner | $754.7K | Open filing |
| 2025-09-08 | Mineralys Therapeutics, Inc. | MLYS | Director | $30.0M | Open filing |
| 2025-03-17 | Mineralys Therapeutics, Inc. | MLYS | Director | $17.5M | Open filing |
| 2025-02-10 | Sionna Therapeutics, Inc. | SION | Director | $20.2M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small Sample | 14.3% (3/21) | 100.0% (3/3) | +12.6% | +10.4% | +5.5% |
| 20D | 3Small Sample | 14.3% (3/21) | 100.0% (3/3) | +19.3% | +22.2% | +15.9% |
| 60D | 2Small Sample | 10.5% (2/19) | 100.0% (2/2) | +28.8% | +28.8% | +13.0% |
| 120D | 1Small Sample | 11.1% (1/9) | 100.0% (1/1) | +23.7% | +23.7% | +23.7% |
Research patterns
- First purchase in 12M
- 5/18
- Large purchase ≥ $100k
- 19/21
- Cluster buying · 15D
- 21/21
- Buying the dip
- 0/1
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.